CD8A and neoplasm: To explore the association between cell components and OS in patients treated with tislelizumab, patients (n = 67) were assigned to subgroups according to the density of PD-L1 + cells, PD-L1 + tumor cells, PD-L1 + Mφ, CD8+ T cells, and Mφ.